Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD
First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and
View HTML
Toggle Summary Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate SAN FRANCISCO , Nov. 08, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc.
View HTML
Toggle Summary Assembly Biosciences Announces November Conference Participation
SAN FRANCISCO , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at various upcoming
View HTML
Toggle Summary Assembly Biosciences Announces Oral Presentation at 2018 AASLD
SAN FRANCISCO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the company will have an oral
View HTML
Toggle Summary Assembly Biosciences to Present at Upcoming Investor Conferences
SAN FRANCISCO , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September: Baird Global Healthcare Conference : Uri Lopatin , MD, Chief Medical Officer, will
View HTML
Toggle Summary Assembly Biosciences Announces Second Quarter 2018 Financial Results
-  ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 -  Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and INDIANAPOLIS , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.
View HTML
Toggle Summary Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection
INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B infection.
View HTML
Toggle Summary Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
INDIANAPOLIS and SAN FRANCISCO , July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share, which included
View HTML
Toggle Summary Assembly Biosciences Announces Pricing of $144 Million Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO , July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share.
View HTML
Toggle Summary Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO , July 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering.
View HTML